SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

GLENMARK PHARMACEUTICALS

BSE: 532296 29 Jun 2025
Healthcare
₹ 1691
Glenmark Pharmaceuticals ltd specializes in Pharmaceuticals within the Healthcare sector.

GLENMARK PHARMACEUTICALS - Share Price & Details

Market Cap
₹48,290
High /Low
1,831 / 1,230
Stock P/E
36.6
Book Value
₹314.0
Dividend Yield
0.15
ROCE
19.4
ROE
₹15.8
Face Value
1.0
PEG Ratio
3.11
EVEBITDA
₹19.9
Debt
2,473
CMP / FCF
-54.4
Debt to equity
₹0.28
NP Ann
1,047
High price all time
1,831
Piotroski score
₹5.0
Graham Number
512.0
No. Eq. Shares
28.2
Net CF
₹-38.5
Net profit
1,047
Price to book value
5.46
Interest Coverage
₹9.56
Low price all time
109.0
Industry PE
32.7
Reserves
₹8,821
Free Cash Flow
₹-1,575

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
GLENMARK PHARMACEUTICALS LTD.NANANANA48,29036.6
BIOCON LTD.44539.04594.044170.02.874738249.3
Narayana Hrudayalaya LimitedNANANANA3889848.8

Peer Comparison Chart


About GLENMARK PHARMACEUTICALS

Glenmark Pharmaceuticals ltd, with Security Code 532296, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Glenmark Pharmaceuticals Ltd soars 0.98%, rises for fifth straight session

(11 Jun 2025)
Glenmark Pharmaceuticals Ltd is quoting at Rs 1631.4, up 0.98% on the day as on 12:44 IST on the NSE. The stock is up 35.62% in last one...
Read more →

Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

(11 Jun 2025)
Glenmark Pharmaceuticals, a research-led, global pharmaceutical company, has announced the upcoming launch of zanubrutinib in India...
Read more →

Glenmark Pharma announces India launch of blood cancer treatment Brukinsa

(10 Jun 2025)
Glenmark Pharma Ltd. has announced the launch of a blood cancer treatment drug, marketed globally as Brukinsa, after it secured approval...
Read more →

Glenmark Pharma To Launch Cancer Treatment Drug Zanubrutinib After DGCA Approval

(10 Jun 2025)
Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the Drugs...
Read more →

Stocks in Focus: Tata Power, Glenmark Pharma, and Others

(10 Jun 2025)
The GIFT Nifty futures, which is an early indicator of the Nifty50 index stocks, was trading higher by 63 points at 25245.
Read more →

Has Glenmark Pharma declared dividend?

(07 Jun 2025)
Yes, Glenmark Pharmaceuticals has declared a 250% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024.
Read more →